SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-----------------
FORM 10-Q
-----------------
(Mark One)
X Quarterly report pursuant to Section 13 or 15(d) of the Securities
-----------Exchange Act of 1934
For the quarterly period ended September 30, 2001
OR
Transition report pursuant to Section 13 or 15 (d) of the
-----------Securities Exchange Act of 1934
Commission File Number: 000-19370
Curative Health Services, Inc.
(Exact name of registrant as specified in its charter)
MINNESOTA 41-1503914
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification Number)
5051 Highway 7, Suite 100
St. Louis Park, MN 55416
(Address of principal executive offices)
Telephone Number (952) 922-0201
150 Motor Parkway
Hauppauge, New York 11788
(631) 232-7000
(Former address of principal executive offices and telephone number)
-------------------------------------
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days:
Yes X No
--------- ---------
As of November 1, 2001 there were 7,237,665 shares of the Registrant's Common
Stock, $.01 par value, outstanding.
INDEX
Part I Financial Information Page No.
--------------------------------------------------------------------------------
Item 1 Financial Statements:
Condensed Consolidated Statements of Operations
Three and Nine Months ended September 30, 2001 and 2000 3
Condensed Consolidated Balance Sheets
September 30, 2001 and December 31, 2000 4
Condensed Consolidated Statements of Cash Flows
Nine Months ended September 30, 2001 and 2000 5
Notes to Condensed Consolidated Financial Statements 6
Item 2 Management's Discussion and Analysis of Financial Condition
and Results of Operations 9
Item 3 Quantitative and Qualitative Disclosures About Market Risk 12
Part II Other Information Page No.
--------------------------------------------------------------------------------
Item 1 Legal Proceedings 13
Item 6 Exhibits and Reports on Form 8-K 13
Signatures 14
2
Part I. Financial Information
------------------------------
Item 1. Financial Statements
Curative Health Services, Inc. and Subsidiaries
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited)
Three Months Ended Nine Months Ended
------------------ -----------------
September 30, September 30,
------------- -------------
2001 2000 2001 2000
---- ---- ---- ----
Revenues $23,764 $18,919 $61,252 $62,709
Costs and operating expenses:
Cost of sales and services 16,907 12,085 42,177 39,753
Selling, general and administrative 6,502 7,017 18,264 20,683
----- ----- ------ ------
Total costs and operating expenses 23,409 19,102 60,441 60,436
------ ------ ------ ------
Income (loss) from operations 355 (183) 811 2,273
Interest income 55 694 766 1,935
-- --- --- -----
Income before taxes 410 511 1,577 4,208
Income taxes 234 202 899 1,675
--- --- --- -----
Net income $176 $309 $678 $2,533
==== ==== ==== ======
Net income per common share, basic $.02 $.04 $.09 $.28
==== ==== ==== ====
Net income per common share, diluted $.02 $.04 $.08 $.27
==== ==== ==== ====
Weighted average common shares, basic 7,186 8,400 7,141 9,135
===== ===== ===== =====
Weighted average common shares, diluted 8,149 8,550 8,133 9,338
===== ===== ===== =====
See accompanying notes
3
Curative Health Services, Inc. and Subsidiaries
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
September 30, December 31,
2001 2000
---- ----
(unaudited)
ASSETS
Cash and cash equivalents $ 6,175 $19,016
Marketable securities held-to-maturity 496 26,978
Accounts receivable, net 19,997 9,843
Deferred tax assets 3,512 2,806
Assets available for sale - 3,683
Inventory 2,165 -
Prepaid and other current assets 780 1,664
--- -----
Total current assets 33,125 63,990
Property and equipment, net 5,859 7,065
Goodwill 34,848 2,988
Other assets 1,037 1,123
----- -----
Total assets $74,869 $75,166
======= =======
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable $ 11,217 $ 7,308
Accrued expenses 7,743 12,288
----- ------
Total current liabilities 18,960 19,596
Stockholders' equity
Common stock 71 71
Additional paid in capital 30,557 30,896
Retained earnings 25,281 24,603
------ ------
Total stockholders' equity 55,909 55,570
Total liabilities and stockholders' equity $74,869 $75,166
======= =======
See accompanying notes
4
Curative Health Services, Inc. and Subsidiaries
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
Nine Months Ended September 30,
2001 2000
-------------------------------
OPERATING ACTIVITIES
Net income $ 678 $ 2,533
Adjustments to reconcile net income to net
cash (used in) provided by operating activities
Equity in operations of investee 290 269
Depreciation and amortization 2,806 3,504
Changes in operating assets and liabilities (7,353) 7,311
----- ------
NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES (3,579) 13,617
INVESTING ACTIVITIES
Notes receivable 3,683 -
Acquisition of eBiocare (38,648) -
Purchase of property and equipment (439) (1,957)
Sales of marketable securities 26,482 4,428
------ ------
NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES (8,922) 2,471
FINANCING ACTIVITIES
Stock repurchases (1,118) (12,656)
Proceeds from exercise of stock options 778 37
----- ------
NET CASH USED IN FINANCING ACTIVITIES (340) (12,619)
----- ------
(DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS (12,841) 3,469
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 19,016 16,215
------ ------
CASH AND CASH EQUIVALENTS AT END OF PERIOD $ 6,175 $19,684
======= =======
SUPPLEMENTAL INFORMATION PERTAINING TO NONCASH
INVESTING AND FINANCING ACTIVITIES:
In March 2000, the Company recorded an increase of $1,417,000 to its investment
in Accordant Health Services, Inc. and a corresponding increase to paid in
capital related to an increase in the value of the Company's equity interest in
Accordant.
See accompanying notes
5
Curative Health Services, Inc. and Subsidiary
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Note 1. Basis of Presentation
The condensed consolidated financial statements are unaudited and reflect all
adjustments (consisting only of normal recurring adjustments) which are, in the
opinion of management, necessary for a fair presentation of the financial
position and operating results for the interim periods. The condensed
consolidated financial statements should be read in conjunction with the
consolidated financial statements for the year ended December 31, 2000 and notes
thereto contained in the Company's Annual Report on Form 10-K filed with the
Securities and Exchange Commission. The results of operations for the three
months ended September 30, 2001 are not necessarily indicative of the results to
be expected for the entire fiscal year ending December 31, 2001.
Note 2. Net Income per Common Share
Net income per common share, basic, is computed by dividing the net income by
the weighted average number of common shares outstanding. Net income per common
share, diluted, is computed by dividing net income by the weighted average
number of shares outstanding plus dilutive common share equivalents. The
following table sets forth the computation of weighted average shares, basic and
diluted, used in determining basic and diluted earnings per share (in
thousands):
Three Months Nine Months
Ended Ended
September 30, September 30,
2001 2000 2001 2000
---- ---- ---- ----
Weighted average shares, basic 7,186 8,400 7,141 9,135
Effect of dilutive stock options 963 150 992 203
--- --- --- ---
Weighted average shares, diluted 8,149 8,550 8,133 9,338
===== ===== ===== =====
Note 3. Purchase of Millennium Health, Inc.
On March 31, 2001 the Company purchased all of the outstanding capital stock of
eBiocare.com, Inc.("eBiocare") which does business as Millennium Health for
$32.3 million in cash and the assumption and repayment of approximately $5
million in debt. eBiocare is a specialty pharmacy which contracts with insurance
companies, government and other payors to provide direct to patient distribution
of biopharmaceutical drugs. The acquisition was accounted for as a stock
purchase and, therefore, operating results of eBiocare have been included in the
accompanying financial statements from the date of acquisition. Purchase price
allocations have been done on a preliminary basis, subject to adjustment.
Goodwill resulting from the acquisition is being amortized over a 20 year
period.
6
Curative Health Services, Inc. and Subsidiaries
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Note 3. Purchase of Millennium Health, Inc. (continued)
Unaudited pro forma results of operations for the nine months ended September
30, 2001 and 2000, assuming the eBiocare acquisition had occurred on January 1,
2000 are as follows (in thousands, except per share data):
Nine Months Ended September 30,
2001 2000
---- ----
Revenues $ 71,963 $ 66,054
====== =======
Net income $ (16) $ 543
====== =======
Net income per share, diluted $ .- $ .06
== ===
The pro-forma operating results shown above are not necessarily indicative of
operations in the period following acquisition.
Note 4. Segment Information
The Company adheres to the provisions of Statement of Financial Accounting
Standards No. 131, "Disclosures about Segments of an Enterprise and Related
Information". The Company has two reportable segments: Specialty Health Services
and Specialty Pharmacy Services. In its Specialty Health Services, the Company
contracts with hospitals to manage outpatient Wound Care Centers. In its
Specialty Pharmacy Services, the Company contracts with insurance companies,
government and other payors to provide direct to patient distribution of
biopharmaceutical drugs. The Company evaluates segment performance based on
income from operations. Intercompany transactions are eliminated to arrive at
consolidated totals.
The following table presents the results of operations and total assets of the
reportable segments of the Company for the three months ended September 30, 2001
(in thousands):
Specialty Specialty Eliminating
Health Pharmacy Entries Total
Revenues $ 11,085 $ 12,679 $ - $ 23,764
====== ====== == ======
(Loss)income from operations $ (379) $ 734 $ - $ 355
====== === == ===
Total assets $ 69,373 $ 8,968 $ (3,472) $ 74,869
====== ===== ======= ======
The following table presents the results of operations and total assets of the
reportable segments of the Company for the nine months ended September 30, 2001
(000's omitted):
Specialty Specialty Eliminating
Health Pharmacy Entries Total
Revenues $ 36,883 $ 24,369 $ - $ 61,252
====== ====== == ======
(Loss)income from operations $ (448) $ 1,259 $ - $ 811
===== ===== == ===
Total assets $ 69,373 $ 8,968 $ (3,472) $ 74,869
====== ===== ======= ======
7
Note 5. Recent Accounting Pronouncements.
In June 2001 the Financial Accounting Standards Board issued Statement No. 142,
Goodwill and Other Intangible Assets. Under Statement 142 (which supersedes APB
Opinion No. 17, Intangible Assets), goodwill and intangible assets with
indefinite lives are no longer amortized but are reviewed annually, or more
frequently if impairment indicators arise, for impairment. Separable intangible
assets that are not deemed to have an indefinite life will continue to be
amortized over their useful lives. The amortization provisions of Statement 142
require non-amortization of goodwill and indefinite lived intangible assets
acquired after June 30, 2001. However, the impairment provisions of Statement
142 apply to these assets upon adoption of Statement 142. With respect to
goodwill and intangible assets acquired prior to July 1, 2001, companies are
required to adopt Statement 142 in their fiscal year beginning after December
15, 2001 (i.e., year beginning January 1, 2002 for Curative Health Services,
Inc.). Although the Company is in process of assessing the impact of adopting
Statement 142, based upon its current level of goodwill and qualifying
intangible assets, management expects the adoption to reduce its 2002 annual
amortization expense by approximately $1,700,000.
8
Item 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations
Overview
Curative Health Services, Inc. is a leading disease management company that
operates in two business segments: Specialty Pharmacy Services and Specialty
Health Services. In its Specialty Pharmacy operations, the Company purchases
biopharmaceutical drugs from manufacturers and then contracts with insurance
companies, government and other payors to provide direct to patient distribution
of and education about these biopharmaceutical drugs. The Company's Specialty
Pharmacy revenues are derived primarily from fees paid by the payors under these
contracts for the purchase and distribution of these biopharmaceuticals. In
addition, as part of its Specialty Pharmacy operations the Company provides
biopharmaceutical product distribution and support services under contract with
retail pharmacies for which it receives service fees. The biopharmaceutical
drugs distributed by the Company are used by patients with chronic conditions
such as hemophilia, hepatitis C, rheumatoid arthritis and multiple sclerosis.
The Company contracts with approximately 170 payors and 3 retail pharmacies.
In its Specialty Health Services operations, the Company contracts with
hospitals to manage outpatient Wound Care Centers. These Wound Care Centers
offer a comprehensive range of services that enable the Company to provide
patient specific wound care diagnosis and treatments on a cost-effective basis.
Currently, the Company has 110 such contracts. The Company also offers an
expanded disease management offering that addresses the diabetic disease state.
Results of Operations
Revenues. The Company's revenues for the third quarter of 2001 increased 26
percent to $23,764,000 compared to $18,919,000 for the third quarter of the
prior fiscal year. The revenue increase is attributable to the addition of
Specialty Pharmacy revenues of $12,679,000 related to the acquisition of
eBiocare, offset by a reduction in Specialty Health Services revenues of
$7,834,000. For the third quarter, Specialty Pharmacy revenues increased
$989,000 or 8.5% as compared to the second quarter of 2001. The increase is
attributable to a 13% increase in hemophilia product sales and a 4% increase in
injectable product sales. The increase in hemophilia sales is attributed to an
increase in hemophilia patients to 181 as compared to 173 at the end of the
second quarter. The Company expects reduced revenues for the Specialty Pharmacy
business in the fourth quarter of 2001 as a result of the termination of
unprofitable injectable product contracts. For the first nine months of 2001
revenues decreased $1,457,000 from $62,709,000 in 2000 to $61,252,000 for the
same period in 2001, a 2 % decrease. The reduction in revenues for the first
nine months of 2001 is attributable to a reduction in Specialty Health Services
revenues of $25,826,000 offset by the addition of $24,369,000 of Specialty
Pharmacy revenues as the result of the eBiocare acquisition. The reduction in
Specialty Health Services revenues is attributable to the termination of 29
hospital based programs during the last 12 months, re-negotiation of existing
contracts which resulted in reduced revenue to the Company, the conversion of 13
under arrangement model programs to management models which have lower revenue
and expenses, and a reduction of Procuren revenues as a result of Cytomedix,
Inc. no longer offering Procuren product. The reduction in Specialty Health
Services revenue was partially offset by the opening of 8 new programs over the
last 12 months. The Company ended the third quarter of 2001 with 110 hospital
based Wound Care Centers operating compared to 133 at the end of the third
quarter 2000. Revenues at existing centers declined 28 percent in the third
quarter of 2001 as compared to the same period in 2000, primarily due to such
contract renegotiations and declining Procuren revenues. Total new patients to
the Wound Care Centers decreased 16 percent from 15,201 in the third quarter of
2000 to 12,765 for the same period in 2001. For the third quarter same store new
patients increased 2.3% over the same period in the prior fiscal year. The
decline in total new patients is attributed to the decline in the total number
of Wound Care Centers operating.
9
Costs of Product Sales and Services. Costs of product sales and services for the
third quarter increased from $12,085,000 in 2000 to $16,907,000 in 2001, an
increase of 40 percent, and for the first nine months of 2001 totaled
$42,177,000 compared to $39,753,000 for the same period in 2000. For the third
quarter of 2001 the increase is attributable to the addition of $10,808,000 of
cost of sales and services related to Specialty Pharmacy operations, offset by a
reduction in Specialty Health Services operation costs of $5,986,000. The
decrease in Specialty Health Services costs is attributable to reduced staffing
and operating expenses of approximately $1,506,000 related to the operation of
110 programs at the end of the third quarter of 2001 compared with 133 programs
operating at the end of the third quarter 2000, and reduced expenditures of
approximately $1,687,000 related to Procuren production. Additionally there were
24 fewer under-arrangement programs in operation at the end of the third quarter
of 2001 as compared to the same period for 2000 at which the services component
of costs is higher than at the Company's other centers due to the additional
clinical staffing and expenses that these models require. For the third quarter
of 2001 this reduction in the number of under-arrangement programs accounted for
approximately $1,334,000 of the decrease in product costs and services. During
2000, the Company eliminated 58 sales positions which resulted in a reduction of
approximately $891,000 in product costs and services for the third quarter of
2001 as compared with the same period in 2000. As a percentage of revenues,
costs of product sales and services for the third quarter of 2001 was 71 percent
compared to 64 percent for the same period in 2000. The increase is primarily
attributable to the addition of Specialty Pharmacy operations, which has lower
gross margins. For the first nine months of 2001 cost of product sales and
services increased 6 percent. The increase is attributed to the addition of
Specialty Pharmacy costs of $20,739,000 offset by a reduction in Specialty
Health Services costs of $18,315,000. The reduction in Wound Care costs is
attributable to reduced staffing and operating expenses of approximately
$4,581,000 related to the operation of 110 programs at the end of the third
quarter 2001 compared with 133 programs operating at the end of the third
quarter 2000, and reduced expenditures of approximately $3,506,000 related to
Procuren production. Additionally, there were 24 fewer under-arrangement
programs in operation at the end of the third quarter of 2001 as compared to the
same period for 2000 at which the services component of costs is higher than at
the Company's other centers due to the additional clinical staffing and expenses
that these models require. For the first nine months of 2001 this reduction in
the number of under-arrangement programs accounted for approximately $4,526,000
of the decrease in Specialty Health Services product costs and services. During
2000, the Company eliminated 58 Wound Care sales positions which resulted in a
reduction of approximately $3,661,000 in product costs and services for the
first nine months of 2001 as compared with the same period in 2000.
10
Selling, General and Administrative. Selling, general and administrative
expenses for the third quarter decreased from $7,017,000 in 2000 to $6,502,000
in 2001 a decrease of 7 percent. The reduction is due to a decrease in
expenditures related to Specialty Health Services operations of $1,652,000
offset by addition of $1,137,000 in selling, general and administrative expenses
related to Specialty Pharmacy. The decrease in Specialty Health Services related
expense is primarily attributable to the positions eliminated at the Company
during 2000 as well as the closing of the Company's Dallas field office. As a
percentage of revenues, selling, general and administrative expenses were 27
percent in the third quarter of 2001 compared to 37 percent for 2000. The
decrease is due to the increased revenue base and lower expenses in 2001. For
the first nine months of 2001 selling, general and administrative expenses
decreased from $20,683,000 in 2000 to $18,264,000, a decrease of 12 percent. The
reduction is due to a decrease in expenditures for the Specialty Health Services
business of $4,790,000 offset by the inclusion of $2,371,000 in selling, general
and administrative expenses related to the Specialty Pharmacy business. The
decrease in the Specialty Health Services related costs is primarily
attributable to the positions eliminated at the Company during 2000 as well as
the closing of the Company's Dallas field office. As a percentage of revenues,
selling, general and administrative expenses were 30 percent for the first nine
months of 2001 compared to 33 percent for 2000.
Net Income. Net income was $176,000 or $0.02 per diluted share in the third
quarter of 2001 compared to $309,000 or $0.04 per diluted share in the third
quarter of 2000. For the first nine months of 2001 net income was $678,000 or
$.08 per diluted share compared to $2,533 or $.27 per diluted share for the same
period in 2000. The decrease in earnings of $133,000 for the third quarter of
2001 is primarily attributable to the recording of $470,000 in goodwill
amortization related to the purchase of eBiocare. For the first nine months of
2001 the decrease in earnings is attributable to the recording of $817,000 of
goodwill amortization related to the eBiocare purchase, an increase in legal
expense related to the Department of Justice and shareholder actions of
$525,000, reduced operating margins in the Specialty Health Services business as
a result of the reduced revenue, offset by the inclusion of operations of the
Specialty Pharmacy business.
Liquidity and Capital Resources.
Working capital was $14.2 million at September 30, 2001 compared to $44.4
million at December 31, 2000. Total cash, cash equivalents and marketable
securities held to maturity as of September 30, 2001 was $6.7 million and was
invested primarily in highly liquid money market funds, commercial paper and
government securities. The Company's cash and cash equivalents and marketable
securities held-to-maturity declined from $46 million at December 31, 2000 to
$6.7 million at September 30, 2001. The decline is primarily attributable to the
use of $38.7 million for the purchase of eBiocare on March 30, 2001. The ratio
of current assets to current liabilities was 3.3:1 at December 31, 2000 and
1.8:1 at September 30, 2001.
11
Cash flows used in operating activities for the first nine months of 2001
totaled $3,579,000 primarily attributable to a reduction in accounts payable and
accrued expenses. Cash flows used in investing activities totaled $8,922,000
primarily attributable to the purchase of eBiocare offset by the sale of
marketable securities to fund the purchase. Cash flows used in financing
activities totaled $340,000, primarily attributable to the Company's repurchase
of shares of common stock offset by stock option exercises.
For the first nine months of 2001, the Company experienced a net increase in
accounts receivable of $10,154,000 primarily attributable to the purchase of
eBiocare. Accounts receivable days outstanding were 76 days as of September 30,
2001 as compared to 61 days at December 31, 2000. Days outstanding for the
Specialty Health Services business was 68 days and for the Specialty Pharmacy
business 83 days at September 30, 2001.
The Company's longer term cash requirements include working capital for the
expansion of its specialty health care and specialty pharmacy businesses. Other
cash requirements are anticipated for capital expenditures in the normal course
of business, the acquisition of software, computers and equipment related to the
Company's management information systems. Additionally the Company expects to
incur significant legal costs related to the Department of Justice actions and
shareholder class action lawsuits filed against the Company (See Legal
Proceedings, Part II Item 1). The Company expects that based on its current
business plan, its existing cash and cash equivalents will be sufficient to
satisfy its current working capital needs. The Company anticipates obtaining a
revolving line of credit to supplement its working capital needs as the result
of the Millennium acquisition and other contingencies. The effects of inflation
and foreign currency translation risks are considered immaterial.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
The Company does not have operations subject to risks of material foreign
currency fluctuations, nor does it use derivative financial instruments in its
operations or investment portfolios. The Company places its investments in
instruments that meet high credit quality standards, as specified in the
Company's investment policy guidelines. The Company does not expect any material
loss with respect to its investment portfolio or exposure to market risks
associated with interest rates.
12
Curative Health Services, Inc. and Subsidiaries
Part II. Other Information
---------------------------
Item 1. Legal Proceedings
With respect to the Company's pending litigation and legal actions previously
disclosed, there have been no material developments other than as disclosed in
Item 3 - "Legal Proceedings" in the Company's Annual Report on form 10K filed
with the SEC for the year ended December 31, 2000.
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits
Exhibit 10.34 Employment Agreement dated September 17, 2001 between Gary
Blackford and the Company.
(b) Form 8-K
There were no reports filed on form 8-K during the quarter.
13
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Dated: November 14, 2001
Curative Health Services, Inc.
(Registrant)
/s/ Gary D. Blackford
-------------------------------------------
Gary D. Blackford
Chief Executive Officer
/s/ Thomas Axmacher
--------------------------------------------
Thomas Axmacher
Chief Financial Officer
(Principal Financial and Accounting Officer)
14
Exhibit10.34
EMPLOYMENT AGREEMENT
THIS EMPLOYMENT AGREEMENT (the "Agreement") is made effective as of
September 17, 2001 (the "Effective Date"), between CURATIVE HEALTH SERVICES,
INC., a Minnesota corporation (the "Company"), and GARY D. BLACKFORD
("Executive").
WHEREAS, the Company wishes to employ Executive in the employ of the
Company as its Chief Executive Officer and Executive desires to accept such
employment; and
WHEREAS, the Company and Executive want the terms and conditions of
Executive's employment to be governed by this Agreement.
NOW, THEREFORE, in consideration of the promises and the mutual covenants
and agreements herein contained, the Company and Executive hereby agree as
follows:
1. Employment
---------
1.1 Employment and Duties. The Company hereby agrees to employ Executive for the
Term (as hereinafter defined) as its Chief Executive Officer, subject to the
direction of the Board of Directors, and in connection therewith, to perform
such duties as he shall reasonably be directed by the Board of Directors to
perform. Executive hereby accepts such employment and agrees to render such
services on the terms and conditions set out herein. Executive shall perform his
duties and carry out his responsibilities hereunder in a diligent manner, shall
use his best efforts to promote the interests of the Company and shall be
faithful in the performance of his duties and in carrying out his
responsibilities.
1.2 Location. The principal location for performance of Executive's services
hereunder shall be Minneapolis, Minnesota, subject to reasonable travel
requirements during the course of such performance.
1.3 Board of Directors. Executive agrees to accept election and to serve or
continue to serve, as the case may be, during the Term as a director of the
Company and of any subsidiary or affiliate of the Company, without any
compensation therefor other than that specified herein, if elected to any such
position by the Board of Directors or by the stockholders of the Company or of
any subsidiary or affiliate, as the case may be. The Company will use its best
efforts to cause and maintain the election of Executive to the Company's Board
of Directors. In connection therewith, the Company shall use its best efforts to
include Executive in the management slate for election as a director at every
annual meeting of shareholders of the Company at which his term as a director
would otherwise expire. Upon the termination of this Agreement or Executive's
employment hereunder for any reason, Executive shall resign from the Board and
from all other positions as an officer or director of any of the Company's
subsidiaries or affiliates.
2. Employment Term
---------------
The term of Executive's employment hereunder (the "Term") shall be deemed
to commence on the Effective Date and shall end on the first anniversary of the
Effective Date, unless sooner terminated as hereinafter provided; provided,
however, that the Term shall be automatically renewed and extended for an
additional period of one (1) year on each anniversary thereafter unless either
party gives a Notice of Termination (as defined below) to the other party at
least three (3) months prior to such anniversary.
3. Compensation and Benefits
-------------------------
3.1 Cash Compensation
(a) Base Salary. The Company shall pay Executive an annual salary of
$350,000 payable in bi-weekly installments, in arrears (the "Base
Salary"). The Base Salary shall be reviewed by the Company's Board of
Directors no less frequently than annually and, in any case, upon the
consummation by the Company of any material acquisition, and, on any
such review, may be increased, but not decreased (unless mutually
agreed upon by Executive and the Company).
(b) Bonus Plan. The Company shall establish a bonus plan for Executive,
under which Executive shall be eligible to receive a bonus for each
year of employment, based upon criteria to be agreed upon by the
Company's Board of Directors and Executive, in an amount up to 50% of
his then current annual base salary; provided that with respect to the
first twelve (12) months of employment, Executive shall receive no
less than 25% of his annual base salary or $87,500. The bonus, if any,
shall be payable within sixty (60) days following the respective
anniversary of the Effective Date. The Company and Executive may
consider in the future revising payments of such bonuses so that such
payments would be made based on the calendar year. The Company and
Executive shall use reasonable efforts to establish the criteria for
bonuses promptly following the Effective Date, and shall review such
criteria prior to each anniversary of the Effective Date, or, if the
Company and Executive revise the payment of such bonuses to a calendar
year, then such review will take place on a yearly basis, while this
Agreement remains in effect.
3.2 Participation in Benefit Plans. Executive shall be entitled to participate
in all employee benefit plans or programs of the Company to the extent that his
position, title, tenure, salary, age, health and other qualifications make him
eligible to participate. The Company does not guarantee the continuance of any
particular employee benefit plan or program during the Term, and Executive's
participation in any such plan or program shall be subject to all terms,
provisions, rules and regulations applicable thereto. If Executive elects not to
participate in the Company's health care plan, but to obtain coverage directly
through Minnesota Blue Cross Blue Shield, or such other insurer as the Company
may approve, the Company shall reimburse Executive for the reasonable cost of
such coverage. Executive will be entitled to twenty (20) days of vacation per
year. For the Benefit Period, if any, (as hereinafter defined) the Company will
arrange to provide Executive with welfare benefits (including life and health
insurance benefits) of substantially similar design and cost to Executive as the
welfare benefits and other employee benefits available to Executive prior to
Executive's or the Company's, as the case may be, receipt of Notice of
Termination (as hereinafter defined). In the event that Executive shall obtain
full-time employment providing welfare benefits during the Benefit Period, such
benefits as otherwise receivable hereunder by Executive shall be discontinued.
3.3 Expenses. The Company will promptly pay or reimburse Executive for all
reasonable and necessary out-of-pocket expenses incurred by him in the
performance of his duties under this Agreement. Executive shall keep detailed
and accurate records of expenses incurred in connection with the performance of
his duties hereunder and reimbursement therefor shall be in accordance with
reasonable policies and procedures to be established from time to time by the
Board.
3.4 Automobile Expenses. During the Term and in accordance with the Company's
Executive Automobile Policy, Executive shall be entitled to the use of an
automobile leased in the name of the Company. The Executive shall be repaid by
the Company for the monthly lease expense for an automobile leased in the name
of the Executive and for all normal automobile operating expenses incurred by
the Executive.
3.5 Stock Options. On the Effective Date, the Company shall grant Executive
Non-Qualified Stock Option awards for the purchase of an aggregate of 380,000
shares of the Company's Common Stock at an exercise price equal to the fair
market value of such shares equal to the closing price of the Company's stock on
the trading day immediately preceding the Effective Date. In addition, if, after
the Effective Date and during the Term, the Company issues shares of its capital
stock in connection with any private placement, public offering or acquisition,
it shall review and discuss in good faith with Executive the granting of
additional stock options. Such stock option awards, if any, will be subject to
such terms and conditions as are set and determined by the Company's Board of
Directors after discussion with Executive.
4. Termination of Employment
-------------------------
4.1 Definitions
(a) "Benefit Period" shall mean (i) the twelve (12) month period commencing on
the Date of Termination which occurs in connection with a termination of
employment described in the first sentence of Section 4.5(a), or (ii) the
forty-eight (48) month period commencing on the Date of Termination which occurs
in connection with a termination of employment described in the first sentence
of Section 4.5(b).
(b) "Cause" shall mean any of the following:
(i) the conviction of Executive of a felony; or
(ii) the material breach by Executive of his agreements or obligations
under this Agreement, if such breach is described in a written notice
to Executive referring to this Section 4.1(b)(v), and such breach has
not been cured within thirty (30) days after receipt of such notice.
(c) A "Change of Control" shall mean any of the following:
(i) a sale of all or substantially all of the assets of the Company;
(ii) the acquisition of more than fifty percent (50%) of the Common Stock
of the Company (with all classes or series thereof treated as a single
class) by any person or group of persons;
(iii)a reorganization of the Company wherein the holders of Common Stock
of the Company receive stock in another company, a merger of the
Company with another company wherein there is a fifty percent (50%) or
greater change in the ownership of the Common Stock of the Company as
a result of such merger, or any other transaction in which the Company
(other than as the parent corporation) is consolidated for federal
income tax purposes or is eligible to be consolidated for federal
income tax purposes with another corporation;
(iv) in the event that the Common Stock is traded on an established
securities market, a public announcement that any person has acquired
or has the right to acquire beneficial ownership of more than fifty
percent (50%) or more of the then-outstanding Common Stock and for
this purpose the terms "person" and "beneficial ownership" shall have
the meanings provided in Section 13(d) of the Securities and Exchange
Act of 1934 or related rules promulgated by the Securities and
Exchange Commission, or the commencement of or public announcement of
an intention to make a tender offer or exchange offer for more than
fifty percent (50%) or more of the then outstanding Common Stock;
(v) a majority of the Board of Directors is not comprised of Continuing
Directors. A "Continuing Director" means a person who is a member of
the Board of Directors of the Company on the date hereof; or
(vi) the Board of Directors of the Company, in its sole and absolute
discretion, determines that there has been a sufficient change in the
share ownership of the Company to constitute a change of effective
ownership or control of the Company; provided, however, that a
reorganization of the Company instituted and approved by the Board of
Directors wherein the holders of Common Stock of the Company receive
stock in another company which becomes the parent company to the
Company so as to create a holding company structure without altering
the relative voting or economic interests of such holders in such
parent company (a "Holding Company Reorganization") shall not be a
Change of Control.
(d) "Date of Termination" shall mean the date specified in the Notice of
Termination (as hereinafter defined) (except in the case of Executive's death,
in which case the Date of Termination shall be the date of death); provided,
however, that if Executive's employment is terminated by the Company other than
for Cause, the date specified in the Notice of Termination shall be at least
thirty (30) days from the date the Notice of Termination is given to Executive
and if Executive's employment is terminated by Executive, the date specified in
the Notice of Termination shall not be more than sixty (60) days from the date
the Notice of Termination is given to the Company.
(e) "Notice of Termination" shall mean a written notice either from the Company
to Executive, or Executive to the Company, that indicates Section 2 or the
specific provision of Section 4 of this Agreement relied upon as the reason for
such termination or nonrenewal, the Date of Termination, and, in reasonable
detail, the facts and circumstances claimed to provide a basis for termination
or nonrenewal pursuant to Section 2 or this Section 4 of this Agreement.
4.2 Termination Upon Death or Disability. This Agreement, and Executive's
employment hereunder, shall terminate automatically and without the necessity of
any action on the part of the Company upon the death of Executive. In addition,
if at any time during the Term the Board of Directors shall determine, based
upon a written opinion of a qualified physician selected by the Board of
Directors, that Executive has become physically or mentally disabled, whether
totally or partially, so that he is unable substantially to perform his duties
and services hereunder for (i) a period of six (6) consecutive months, or (ii)
for shorter periods aggregating six (6) months during any twelve (12) month
period, the Company may at any time after the last day of the sixth consecutive
month of disability or the day on which the shorter periods of disability shall
have equaled an aggregate of six (6) months, by written notice to Executive (but
before Executive has recovered from such disability), terminate this Agreement
and Executive's employment hereunder.
4.3 Company's and Executive's Right to Terminate--Prior to and Not in Connection
with a Change of Control. Prior to a Change of Control, this Agreement and
Executive's employment hereunder may be terminated at any time by the Company,
with or without Cause, upon at least thirty (30) days prior written notice to
Executive, and by Executive, at any time and for any reason, upon at least sixty
(60) days prior written notice to the Company. Any termination of Executive's
employment by the Company without Cause prior to a Change of Control that occurs
at the request or insistence of any person (other than the Company) relating to
such Change of Control shall be deemed to have occurred after the Change of
Control for the purposes of this Agreement.
4.4 Company's and Executive's Right to Terminate--Following or in Connection
with a Change of Control. Following or in connection with a Change of Control,
this Agreement and Executive's employment hereunder may be terminated at any
time (i) by the Company, with or without Cause, upon at least thirty (30) days
prior written notice to Executive, and (ii) by Executive for any reason upon at
least sixty (60) days prior written notice to the Company. Executive's right to
terminate his employment pursuant to this Section 4.4 shall not be affected by
incapacity due to physical or mental illness.
4.5 Compensation Upon Termination
(a) Termination Prior to and Not in Connection with a Change of Control. In the
event that (i) the Company terminates (or elects not to renew) this Agreement
without Cause or (ii) Executive terminates this Agreement due to the breach by
the Company of its obligations hereunder which continue for thirty (30) days
after written notice thereof from Executive to the Company, and such termination
(or nonrenewal) described in clauses (i) or (ii) occurs prior to and not in
connection with any Change of Control, Executive shall be entitled to receive
his Base Salary through the Date of Termination, the welfare benefits described
in Section 3.2 for the Benefit Period, and not later than thirty (30) days after
the Date of Termination, a lump sum severance payment equal to the sum of
Executive's then Current Base Salary plus the maximum payment that could have
been made to Executive under Section 3.1(b) hereof for the contract year during
which said termination occurs, as if Executive had been employed for the entire
contract year. If such payments are made and benefits provided pursuant to the
preceding clause (ii), such payments and benefits are agreed to be liquidated
damages and not a penalty, and Executive shall have no other claims against the
Company. In the event this Agreement is terminated (or not renewed) for any
reason other than as described in the preceding clauses (i) and (ii), and such
termination (or nonrenewal) occurs prior to and not in connection with a Change
of Control, Executive shall not be entitled to the continuation of any
compensation, bonuses or benefits provided hereunder, or any other payments
following the Date of Termination, other than Base Salary earned through such
Date of Termination.
(b) Termination Following or in Connection with a Change of Control. In the
event this Agreement is terminated (or not renewed) for any reason, and such
termination (or nonrenewal) occurs in connection with or following a Change of
Control, Executive shall not be entitled to the continuation of any
compensation, bonuses or benefits provided hereunder, or any other payments
following the Date of Termination, other than Base Salary earned through the
Date of Termination, the benefits described in Section 3.2 for the Benefit
Period, and the payment described in Section 5.2 to the extent not previously
paid.
(c) At Executive's option to be exercised by written notice to the Company, the
severance benefits payable under this Section 4.5 shall be paid in accordance
with the Company's normal payroll procedures over the twelve (12) month or
longer period as contemplated by Section 4.5(b), as the case may be,
corresponding to the amount of the payments instead of in a lump sum.
(d) Anything to the contrary contained herein notwithstanding, as a condition to
Executive receiving severance benefits to be paid pursuant to this Section 4.5,
Executive shall execute and deliver to the Company a general release in form and
substance reasonably satisfactory to the Company releasing the Company and its
officers, directors, employees and agents from all liabilities, claims and
obligations of any nature whatsoever, excepting only the Company's obligations
under this Agreement, under any Stock Option Award Agreements, and under any
other employee benefit plans or programs in which Executive participates under
Section 3.2 hereof, subject to all terms and conditions of such plans or
programs and this Agreement.
(e) Anything to the contrary contained herein notwithstanding, in the event that
any payment or benefit received or to be received by Executive in connection
with a Change in Control of the Company or termination of Executive's employment
constitutes a "parachute payment" within the meaning of Section 280G(b)(2) of
the Internal Revenue Code of 1986, as amended (the "Code") which would be
subject to the excise tax imposed by Section 4999 of the Code (the "Excise
Tax"), then the Company shall pay Executive in cash an additional amount (the
"Gross-Up Payment") such that, after payment by Executive of all taxes,
including but not limited to income taxes (and any interest and penalties
imposed with respect thereto) and the Excise Tax imposed upon the Gross-Up
Payment, Executive retains an amount of the Gross-Up Payment equal to the Excise
Tax imposed on the parachute payments.
5. Covenants
---------
5.1 Holding Company Reorganization. In the event of a Holding Company
Reorganization, (i) the Company shall assign this Agreement to the ultimate
parent company such that Executive becomes the Chief Executive Officer of such
parent, and (ii) all stock option awards then held by Executive shall be
converted into identical stock options awards to purchase capital stock of such
parent.
5.2 Change of Control. Not later than thirty (30) days after a Change of
Control, Executive shall receive a lump sum payment equal to the product of two
(2) times the sum of Executive's then current annual Base Salary plus the
maximum payment that could have been made to Executive under Section 3.1(b)
hereof for the contract year during which the Change of Control occurs, as if
Executive has been employed for the entire contract year. In addition, to the
extent not otherwise required under the Company's Stock Option Plan or any award
agreement with Executive, any unvested stock option awards theretofore awarded
to Executive shall vest and become immediately exercisable in full.
5.3 Trade Secrets and Confidential Information. Executive agrees that he shall,
during the course of his employment and thereafter, hold inviolate and keep
secret all documents, materials, knowledge or other confidential business or
technical information of any nature whatsoever disclosed to or developed by him
or to which he had access as a result of his employment (hereinafter referred to
as "Confidential Information"). Such Confidential Information shall include
technical and business information, including, but not limited to, inventions,
research and development, engineering, products, designs, manufacture, methods,
systems, improvements, trade secrets, formulas, processes, marketing,
merchandising, selling, licensing, servicing, customer lists, records or
financial information, manuals or Company strategy concerning its business,
strategy or policies. Executive agrees that all Confidential Information shall
remain the sole and absolute property of the Company. During the course of his
employment, Executive shall not use, disclose, disseminate, publish, reproduce
or otherwise make available such Confidential Information to any person, firm,
corporation or other entity, except for the purpose of conducting business on
behalf of the Company. Following the Term, Executive shall not use, disclose,
disseminate, publish, reproduce or otherwise make available such Confidential
Information to any person, firm, corporation or other entity. Upon termination
of his employment with the Company, Executive will leave with or deliver to the
Company all records and any compositions, articles, devices, equipment and other
items which disclose or embody Confidential Information including all copies or
specimens thereof, whether prepared by him or by others. The foregoing
restrictions shall not apply to any knowledge or information which is now public
or which subsequently becomes publicly known (other than as a breach of this
Agreement) or that Executive obtains from a third party under no obligation of
confidentiality to the Company.
5.4 Executive Employment. During the Term, Executive shall devote substantially
all of his working time to the business of the Company. The parties acknowledge
that during the Term the Executive will, subject to the requirement of the
preceding sentence, be entitled to engage in other activities of a business,
professional or commercial nature for which he may receive compensation.
5.5 Non-Solicitation. For one (1) year after termination of employment with the
Company for any reason, the Executive shall not directly or indirectly solicit
or hire, or assist any other person in soliciting or hiring, any employee of the
Company (as of the date of termination) or any person who, as of the date of
termination, was in the process of being recruited by the Company or induce any
such employee to terminate his or her employment with the Company, until 30 days
after he has first given written notice to the Company of his intention to
engage in such activity and identified in such writing the person or persons who
he intends to solicit unless the Company has, prior to the expiration of such 30
day period in writing waived such requirement as to the person or persons
identified in the Executive's notice.
6. Miscellaneous
-------------
6.1 Notices. Any notice required or permitted to be delivered hereunder shall be
in writing and shall be deemed to be delivered on the earlier of (i) the date
received, or (ii) the date of delivery, refusal or non-delivery indicated on the
return receipt, if deposited in a United States Postal Service depository,
postage prepaid, sent registered or certified mail, return receipt requested,
addressed to the party to receive the same at the address of such party set
forth below, or at such other address as may be designated in a notice delivered
or mailed as herein provided.
To Company: Curative Health Services, Inc.
150 Motor Parkway, 4th Floor
Hauppauge, NY 11788
Executive: Gary D. Blackford
14931 Boulder Pointe Rd.
Eden Prairie, MN 55347
6.2 Headings. The headings of the articles and sections of this Agreement are
inserted for convenience only and shall not be deemed a part of or affect the
construction or interpretation of any provision hereof.
6.3 Modifications; Waiver. No modification of any provision of this Agreement or
waiver of any right or remedy herein provided shall be effective for any purpose
unless specifically set forth in a writing signed by the party to be bound
thereby. No waiver of any right or remedy in respect of any occurrence or event
on one occasion shall be deemed a waiver of such right or remedy in respect of
such occurrence or event on any other occasion.
6.4 Entire Agreement. This Agreement contains the entire agreement of the
parties with respect to the subject matter hereof and supersedes all other
agreements, oral or written, heretofore made with respect thereto, including,
without limitation, the Original Agreement.
6.5 Severability. Any provision of this Agreement prohibited by or unlawful or
unenforceable under any applicable law of any jurisdiction shall as to such
jurisdiction be ineffective without affecting any other provision hereof. To the
full extent, however, that the provisions of such applicable law may be waived,
they are hereby waived, to the end that this Employment Agreement be deemed to
be a valid and binding agreement enforceable in accordance with its terms.
6.6 Controlling Law; Jurisdiction. This Agreement has been entered into by the
parties in the State of Minnesota and shall be continued and enforced in
accordance with the laws of that State. The parties agree that United States
District Court for the District of Minnesota shall have sole and exclusive
jurisdiction over any lawsuit or proceeding relating to or arising from this
Agreement. If such court lacks subject matter jurisdiction, the parties agree
that the Minnesota state courts shall have sole and exclusive jurisdiction.
6.7 Assignments. The Company shall have the right to assign this Agreement and
to delegate all rights, duties and obligations hereunder to any entity that
controls the Company, that the Company controls or that may be the result of the
merger, consolidation, acquisition or reorganization of the Company and another
entity. In such event, the term "Company" shall refer to such assignee.
Executive agrees that this Agreement is personal to him and his rights and
interest hereunder may not be assigned, nor may his obligations and duties
hereunder be delegated (except as to delegation in the normal course of
operation of the Company), and any attempted assignment or delegation in
violation of this provision shall be void.
6.8 Attorney Fees. In the event of litigation between the parties to enforce
their respective rights under this Agreement, the prevailing party shall be
entitled to receive from the non-prevailing party reimbursement of the
prevailing party's reasonable attorney's fees and costs at all levels of trial
and appeal.
IN WITNESS WHEREOF, the parties have executed this Agreement as of the
Effective Date.
CURATIVE HEALTH SERVICES, INC.
By:_________________________________
Its: Chairman
---------------------------------
Executive